Laccure's Antibiotic-Free OTC Product for Bacterial Vaginosis Ready for Commercialisation

Helsingborg, Sweden (ots/PRNewswire) -

The Swedish company Laccure AB has developed a breakthrough
women's health product that is effective, safe and user-friendly.
Laccure's owners are now aiming to divest the company to a buyer with
appropriate resources to launch the product.

The manufacturing process for the new product, Laccure(R) Pessary,
has now been scaled up and the product is ready for market
introduction. Laccure has therefore initiated a search for an
established company interested in acquiring Laccure and launching the
product. Evli Corporate Finance is retained for the exit process.

"We are proud to announce that the final development stage, the
up-scaling of the manufacturing process for Laccure(R) Pessary, our
new antibiotic-free, non-prescription product for the treatment and
prevention of bacterial vaginosis, is now completed. The product is
thus ready for launch. Our objective from the start of the project
has been to sell Laccure to a company that will take the product to
market," says Dr Jeanette Robertsson, CEO of Laccure AB.

Bacterial Vaginosis

Bacterial vaginosis (BV) is the most common vaginal infection in
women of childbearing age, affecting more than 300 million women
worldwide each year. Today, there is a lack of effective and safe
products that are also user-friendly and can be dosed with low
frequency. Women are often embarrassed at having BV and their quality
of life is negatively affected. BV is an imbalance of naturally
occurring vaginal bacterial flora, resulting in a lack of vaginal
acidity, discharge with a pronounced foul odour and inhibition of
normal lactobacilli growth. Frequent recurrences are common.

Laccure(R) Pessary

The new, patented product is based on a proprietary substance that
releases lactic acid over several days to decrease the elevated
vaginal pH. The development work has focused on creating a
user-friendly, non-smear product that is easy to insert and highly
effective. This has been demonstrated in clinical studies, in which
80% of the women were free of their BV after a single dose.
Laccure(R) Pessary need only be administered once a month to prevent
recurrence. Laccure(R) Pessary is CE-marked as a Class IIa medical
device and is now ready for market introduction in the EU/EES
countries.

Laccure AB

Laccure AB was founded in 2007 and is a project company within
P.U.L.S. http://www.laccure.com and http://www.pulsinvest.se

ots Originaltext: Laccure AB
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Sven-Inge Svensson, Chairman of the Board,
sven-inge.svensson@laccure.com; Dr Jeanette Robertsson, CEO,
jeanette.robertsson@laccure.com